{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["42(5)"],"submitter":["Ziegler DA"],"pubmed_abstract":["<h4>Background</h4>The abscopal effect (AbE) refers to the regression of non-irradiated tumors following localized radiotherapy (RT), suggesting a systemic immune-mediated response. The combination of RT with immunotherapy (IO) has been proposed to enhance the AbE by overcoming RT-induced immunosuppressive mechanisms, but robust evidence, specifically in non-small cell lung cancer (NSCLC), is lacking. This study aimed to determine the prevalence of the AbE and its association with progression-free survival (PFS) and overall survival (OS) in metastatic lung cancer patients receiving RT and IO.<h4>Materials and methods</h4>We analyzed consecutive metastatic lung cancer patients who received IO at a certified lung cancer center in Germany between 2009 and 2021. Inclusion required RT to at lea"],"journal":["Clinical & experimental metastasis"],"pagination":["56"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12474601"],"repository":["biostudies-literature"],"pubmed_title":["The abscopal effect in metastatic lung cancer: a retrospective analysis of combined radiotherapy and immunotherapy."],"pmcid":["PMC12474601"],"pubmed_authors":["Donath S","Fischer LA","Rieken S","Ambold M","Schirmer MA","Guhlich M","Droge LH","Kieslich B","El Shafie R","Bensberg J","von Diest LA","von Hammerstein-Equord A","Leu M","Andreas S","Braulke F","Rittmeyer A","Ziegler DA","Ziegler S"],"additional_accession":[]},"is_claimable":false,"name":"The abscopal effect in metastatic lung cancer: a retrospective analysis of combined radiotherapy and immunotherapy.","description":"<h4>Background</h4>The abscopal effect (AbE) refers to the regression of non-irradiated tumors following localized radiotherapy (RT), suggesting a systemic immune-mediated response. The combination of RT with immunotherapy (IO) has been proposed to enhance the AbE by overcoming RT-induced immunosuppressive mechanisms, but robust evidence, specifically in non-small cell lung cancer (NSCLC), is lacking. This study aimed to determine the prevalence of the AbE and its association with progression-free survival (PFS) and overall survival (OS) in metastatic lung cancer patients receiving RT and IO.<h4>Materials and methods</h4>We analyzed consecutive metastatic lung cancer patients who received IO at a certified lung cancer center in Germany between 2009 and 2021. Inclusion required RT to at lea","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-04T07:54:17.171Z","creation":"2026-05-07T03:08:46.292Z"},"accession":"S-EPMC12474601","cross_references":{"pubmed":["41003851"],"doi":["10.1007/s10585-025-10375-w"]}}